

CINK4 10/19

ALTERNATE NAMES: trans-4-[[6-(Ethylamino)-2-[[1-(phenylmethyl)-1H-indol-5-yl]amino]-4-pyrimidinyl]amino]-cyclohexanol; 4-

[[2-[(1-benzylindol-5-yl)amino]-6-(ethylamino)pyrimidin-4-yl]amino]cyclohexan-1-ol; Cdk4/6 Inhibitor IV

**CATALOG #**: B2929-5 5 mg B2929-25 25 mg

STRUCTURE:

MOLECULAR WEIGHT: 456.58

**CAS NUMBER:** 359886-84-3

APPEARANCE: A crystalline solid

PURITY: 95%

SOLUBILITY: ~1 mg/ml in ethanol

~30 mg/ml in DMSO and DMF

**DESCRIPTION:** CINK4 is a triaminopyrimidine derivative that inhibits Cdk4/cyclin D1 and Cdk6/cyclin D1 activity with

 $IC_{50}$  values of 1.5 and 5.6  $\mu$ M, respectively. It reduces retinoblastoma protein phosphorylation at Ser780 and Ser795 and induces cell cycle arrest in the G1 phase in U2OS and MRC-5 cells at 5-10  $\mu$ M. Administration of CINK4 at 30 mg/kg, i.p. for 29 days, suppresses tumor growth in mice bearing human

HCT116 colon carcinoma xenografts.

**STORAGE TEMPERATURE:** -20°C. Store in the dark. Product is light sensitive.

REFERENCE: Soni, R., O'Reilly, T., Furet, P., et al. Selective in vivo and in vitro effects of a small molecule inhibitor of

cyclin-dependent kinase 4. Journal of the National Cancer Institute 93(6), 436-446 (2001).

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

**RELATED PRODUCTS:** 

Ribociclib (LEE011) (Cat. No. 9481 Cdk4 Inhibitor (Cat. No. B2928) Flavopiridol (Cat. No. 2090) Riviciclib hydrochloride (Cat. No. B2567) Dinaciclib (Cat. No. 9537)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.